The pathogenesis of narcolepsy, current treatments and prospective therapeutic targets

Bibliography

• Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol. 1994;35(6):709–716.
   PubMed Web of Science ®Google Scholar
• Honda Y. Census of narcolepsy, cataplexy and sleep life among teen-agers in Fujisawa city. Sleep Res Online. 1979;8:19.
   Google Scholar
• Tashiro T, Kanbayashi T, Hishikawa Y. An epidemiological study of narcolepsy in Japanese. In: The Fourth International Symposium on Narcolepsy; 1994 June 16–17; Tokyo, p. 13.
   Google Scholar
• Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep. 1987 Dec;10(6):608–609.
   PubMed Web of Science ®Google Scholar
• Okun ML, Lin L, Pelin Z, et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep. 2002;25(1):27–35.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001 Dec 11;57(11):2029–2033.
   PubMed Web of Science ®Google Scholar
• Inocente CO, Gustin MP, Lavault S, et al. Quality of life in children with narcolepsy. CNS Neurosci Ther. 2014;20(8):763–771.
   PubMed Web of Science ®Google Scholar
• Rocca FL, Pizza F, Ricci E, et al. Narcolepsy during childhood: an update. Neuropediatrics. 2015 Jun;46(3):181–198.
   PubMed Web of Science ®Google Scholar
• Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997 May;52(1):27–78.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol. 2003 Nov;114(11):2000–2017.
   PubMed Web of Science ®Google Scholar
• Guilleminault C. Narcolepsy syndrome. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 2nd ed. Philadelphia (PA): Saunders; 1994. p. 549–561.
   Google Scholar
• Juji T, Satake M, Honda Y, et al. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens. 1984 Nov;24(5):316–319.
   PubMed Web of Science ®Google Scholar
• Gelb M, Guilleminault C, Kraemer H, et al. Stability of cataplexy over several months–information for the design of therapeutic trials. Sleep. 1994;17(3):265–273.
   PubMed Web of Science ®Google Scholar
• Hishikawa Y, Wakamatsu H, Furuya E, et al. Sleep satiation in narcoleptic patients. Electroencephalogr Clin Neurophysiol. 1976;41:1–18.
   PubMedGoogle Scholar
• Broughton R, Dunham W, Newman J, et al. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroenceph Clin Neurophysiol. 1988;70:473–481.
   PubMedGoogle Scholar
• Montplaisir J, Billard M, Takahashi S, et al. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psych. 1978;13(1):78–89.
   Web of Science ®Google Scholar
• Godbout R, Montplaisir J. Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep. In: Koella WP, Ruther E, Schulz H, editors. Sleep ‘84. Gustav: Fischer Verlag; 1985. p. 380–382.
   Google Scholar
• Mosko SS, Shampain DS, Sassin JF. Nocturnal REM latency and sleep disturbance in narcolepsy. Sleep. 1984;7:115–125.
   PubMed Web of Science ®Google Scholar
• Mayer G, Pollmächer T, Meier-Ewert K, et al. Zur Einschätzung des Behinderungsgrades bei Narkolepsie. Gesundh-Wes. 1993;55:337–342.
   PubMedGoogle Scholar
• Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol. 1992;32(1):3–10.
   PubMed Web of Science ®Google Scholar
• Chokroverty S. Sleep apnea in narcolepsy. Sleep. 1986;9(1):250–253.
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York (NY): Spectrum Publications; 1976.
   Google Scholar
• Juji T, Matsuki K, Tokunaga K, et al. Narcolepsy and HLA in the Japanese. Ann N Y Acad Sci. 1988;540:106–114.
   PubMedGoogle Scholar
• Baker TL, Foutz AS, McNerney V, et al. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol. 1982 Mar;75(3):729–742.
   PubMed Web of Science ®Google Scholar
• Nishino S, Riehl J, Hong J, et al. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res. 2000;38(4):437–446.
   PubMed Web of Science ®Google Scholar
• Kaitin KI, Kilduff TS, Dement WC. Evidence for excessive sleepiness in canine narcoleptics. Electroencephalogr Clin Neurophysiol. 1986;64(5):447–454.
   PubMedGoogle Scholar
• Hungs M, Fan J, Lin L, et al. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res. 2001 Apr;11(4):531–539.
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999 Aug 6;98(3):365–376.
   PubMed Web of Science ®Google Scholar
• Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis. 2001 Jun;8(3):525–534.
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000 Jan 1;355(9197):39–40.
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999 Aug 20;98(4):437–451.
   PubMed Web of Science ®Google Scholar
• Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30(2):345–354.
   PubMed Web of Science ®Google Scholar
• Tabuchi S, Tsunematsu T, Black SW, et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci. 2014 May 7;34(19):6495–6509.
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron. 2003 Jun 5;38(5):715–730.
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991–997.
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002 Oct;59(10):1553–1562.
   PubMed Web of Science ®Google Scholar
• Icsd-2. editor. ICSD-2-International classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester (IL): American Academy of Sleep Medicine; 2005.
   Google Scholar
• ICSD-3, editor. International classification of sleep disorders. 3rd ed. Rochester (MN): American Sleep Disorders Association; 2014.
   Google Scholar
• Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997 Nov;20(11):1012–1020.
   PubMed Web of Science ®Google Scholar
• Aran A, Nevsimalova S, Plazzi G, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979–983.
   PubMed Web of Science ®Google Scholar
• Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009 Jun;41(6):708–711.
   PubMed Web of Science ®Google Scholar
• Zarocostas J. WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children. Bmj. 2011;342:d909.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep. 2010 Nov;33(11):1428–1430.
   PubMed Web of Science ®Google Scholar
• Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70(3):410–417.
   PubMed Web of Science ®Google Scholar
• Jones BE. Basic mechanism of sleep-wake states. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4th ed. Philadelphia: Elsvier Saunders; 2005. p. 136–153.
   Google Scholar
• Nishino S, Kotorii N. Overview of management of narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors. Narcolepsy. Totowa: Humana. Forthcoming 2009.
   Google Scholar
• Jouvet M. The role of monoamines and acethylcholine-containing neurons in the regulation of the sleep-waking cycle. Ergebn Physiol. 1972;64:166–307.
   PubMedGoogle Scholar
• Nishino S. Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors. Narcolepsy. Totowa: Humana. Forthcoming 2009.
   Google Scholar
• Nishino S, Mignot E, Dement WC. Sedative-hypnotics. In: Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. 2nd ed. Washington (DC): American Psychiatric Press; 2004. p. 651–684.
   Google Scholar
• Steinfels GF, Heym J, Streckjer RE, et al. Behavioral correlates of dopaminergic activity in freely moving cats. Brain Res. 1983;258:217–228.
   PubMed Web of Science ®Google Scholar
• Guilleminault C. Narcolepsy and its differential diagnosis. In: Guilleminault C, editor. Sleep and it disorders in children. New York (NY): Raven Press; 1987. p. 181–194.
   Google Scholar
• Trulson ME. Simultaneous recording of substantia nigra neurons and voltametric release of dopamine in the caudate of behaving cats. Brain Res Bull. 1985;15:221–223.
   PubMed Web of Science ®Google Scholar
• Ljungberg T, Apicella P, Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol. 1992 Jan;67(1):145–163.
   PubMed Web of Science ®Google Scholar
• Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci. 2006;26(1):193–202.
   PubMed Web of Science ®Google Scholar
• Moller JC, Stiasny K, Cassel W, et al. [“Sleep attacks” in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?]. Nervenarzt. 2000;71(8):670–676.
   PubMed Web of Science ®Google Scholar
• Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep. 1994 Dec;17(8 Suppl):S97–S102.
   PubMed Web of Science ®Google Scholar
• Roehrs T, Zorick F, Wittig R, et al. Alerting effects of naps in patients with narcolepsy. Sleep. 1986;9(1 Pt 2):194–199.
   PubMed Web of Science ®Google Scholar
• Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs. 1984 Dec;16(6):326–334.
   PubMedGoogle Scholar
• Hirai N, Nishino S. Recent advances in the treatment of narcolepsy. Curr Treat Options Neurol. 2011 Oct;13(5):437–457.
   PubMed Web of Science ®Google Scholar
• Mitler MM, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep. 1994 Jun;17(4):352–371.
   PubMed Web of Science ®Google Scholar
• Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep. 1991 Jun;14(3):218–220.
   PubMed Web of Science ®Google Scholar
• Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960 Dec;21:704–706.
   PubMedGoogle Scholar
• Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol. 1974 Jan;30(1):90–93.
   PubMedGoogle Scholar
• Parkes JD, Baraitser M, Marsden CD, et al. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand. 1975 Nov;52(5):337–353.
   PubMed Web of Science ®Google Scholar
• Passouant P, Billiard M. [Narcolepsy]. Rev Prat. 1976;26(27):1917–1923.
   PubMedGoogle Scholar
• Rogers AE, Aldrich MS, Berrios AM, et al. Compliance with stimulant medications in patients with narcolepsy. Sleep. 1997 Jan;20(1):28–33.
   PubMed Web of Science ®Google Scholar
• Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep. 2005 Jun;28(6):667–672.
   PubMed Web of Science ®Google Scholar
• Yoss RE, Daly D. Treatment of narcolepsy with ritalin. Neurology. 1959 Mar;9(3):171–173.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Cravens J. Sleep: effects of d- and l-amphetamine in man and in rat. Psychopharmacology (Berl). 1976;50(2):171–175.
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal DS. Neurochemistry of amphetamine. In: Cho AK, Segal DS, editors. Psychopharmacology, toxicology and abuse. San Diego (CA): Academic Press; 1994. p. 81–113.
   Google Scholar
• [Tablets prescribing information]NuvigilTM (armodafinil) Tablets prescribing information; [ cited 2015 Oct 14]. Available from: http://www.nuvigil.com/PDF/Full_Prescribing_Information.pdf
   Google Scholar
• Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994 Aug;17(5):436–437.
   PubMed Web of Science ®Google Scholar
• Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1(1):49–61.
   PubMedGoogle Scholar
• Dopheide MM, Morgan RE, Rodvelt KR, et al. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol. 2007;568(1–3):112–123.
   PubMed Web of Science ®Google Scholar
• Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001 Mar 1;21(5):1787–1794.
   PubMed Web of Science ®Google Scholar
• Duteil J, Rambert FA, Pessonnier J, et al. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol. 1990;180(1):49–58.
   PubMed Web of Science ®Google Scholar
• Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591(2):319–326.
   PubMed Web of Science ®Google Scholar
• Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep. 1995 Dec;18(10):817–826.
   PubMed Web of Science ®Google Scholar
• Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther. 1997 Nov;283(2):757–769.
   PubMed Web of Science ®Google Scholar
• Nishino S, Fruhstorfer B, Arrigoni J, et al. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther. 1993 Mar;264(3):1079–1084.
   PubMed Web of Science ®Google Scholar
• Qu WM, Huang ZL, Xu XH, et al. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci. 2008;28(34):8462–8469.
   PubMed Web of Science ®Google Scholar
• Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132(4):1027–1034.
   PubMed Web of Science ®Google Scholar
• Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007 Apr 15;73(8):1157–1171.
   PubMed Web of Science ®Google Scholar
• Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561–569.
   PubMed Web of Science ®Google Scholar
• Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128–14133.
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000 Nov 15;20(22):8620–8628.
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003;339(2):143–146.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Jama. 2009 Mar 18;301(11):1148–1154.
   PubMed Web of Science ®Google Scholar
• Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc). 2008 Jun;44(6):395–414.
   PubMed Web of Science ®Google Scholar
• Iijima S, Sugita Y, Teshima Y, et al. Therapeutic effects of mazindol on narcolepsy. Sleep. 1986;9(1 Pt 2):265–268.
   PubMed Web of Science ®Google Scholar
• Nishino S. Adrenergic, but not dopaminergic, uptake inhibition reduces REM sleep and cataplexy concomitantly. Sleep Res Online. 1997;26:445.
   Google Scholar
• Radulovacki M, Virus RM, Djuricic-Nedelson M, et al. Adenosine analogs and sleep in rats. J Pharmacol Exp Ther. 1984 Feb;228(2):268–274.
   PubMed Web of Science ®Google Scholar
• Porkka-Heiskanen T, Strecker RE, Thakkar M, et al. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 1997;276(5316):1265–1268.
   PubMed Web of Science ®Google Scholar
• Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8(7):858–859.
   PubMed Web of Science ®Google Scholar
• Chen JF, Beilstein M, Xu YH, et al. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience. 2000;97(1):195–204.
   PubMed Web of Science ®Google Scholar
• Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1970–1975.
   PubMed Web of Science ®Google Scholar
• Chen JF, Moratalla R, Yu L, et al. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology. 2003;28(6):1086–1095.
   PubMed Web of Science ®Google Scholar
• Lazarus M, Shen HY, Cherasse Y, et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci. 2011 Jul 6;31(27):10067–10075.
   PubMed Web of Science ®Google Scholar
• Okuro M. Evaluations of wake promoting effects of paraxanthine in orexin/ataxin-3 narcoleptic mice. Sleep. 2009;32(Abstract Supplement):A35.
   Google Scholar
• Kuczenski R, Segal DS, Cho AK, et al. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995 Feb;15(2):1308–1317.
   PubMed Web of Science ®Google Scholar
• Raynal D, Guilemminault C, Dement WC. Polygraphic aspects of narcolepsy. In: Guilemminault CWCD, Passouant P, editors. Narcolepsy. New York (NY): Spectrum Publications, Inc; 1976. p. 669–684.
   Google Scholar
• Baldessarini R. How do antidepressants work? In: Davis JM, Mass JW, editors. The affective disorders. Wachington (DC): American Psychiatric Press; 1983. p. 243–260.
   Google Scholar
• Thorpy M, Goswami M. Treatment of narcolepsy. In: Thorpy M, editor. Handbook of sleep disorders. New York (NY): Marcel Dekker, Inc; 1990. p. 235–258.
   Google Scholar
• Langdon N, Shindler J, Parkes JD, et al. Fluoxetine in the treatment of cataplexy. Sleep. 1986 Jun;9(2):371–373.
   PubMed Web of Science ®Google Scholar
• Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl). 1993;113(1):76–82.
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep. 1986;9(1 Pt 2):280–284.
   PubMed Web of Science ®Google Scholar
• Schrader H, Kayed K, Bendixen Markset AC, et al. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 1986 Oct;74(4):297–303.
   PubMed Web of Science ®Google Scholar
• Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. [Status cataplecticus induced by abrupt withdrawal of clomipramine]. Neurologia. 2002;17(2):113–116.
   PubMed Web of Science ®Google Scholar
• Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 1993 Dec;16(8):706–712.
   PubMed Web of Science ®Google Scholar
• Izzi F, Placidi F, Marciani MG, et al. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases. Sleep Med. 2009;10(1):153–154.
   PubMed Web of Science ®Google Scholar
• Poryazova R, Siccoli M, Werth E, et al. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology. 2005;65(6):967–968.
   PubMed Web of Science ®Google Scholar
• Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York (NY): Spectrum Publication; 1976. p. 625–638.
   Google Scholar
• Wyatt RJ, Fram DH, Buchbinder R, et al. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med. 1971;285(18):987–991.
   PubMed Web of Science ®Google Scholar
• Koran LM, Raghavan S. Fluoxetine for isolated sleep paralysis. Psychosomatics. 1993 Mar–Apr;34(2):184–187.
   PubMed Web of Science ®Google Scholar
• Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 1986;9(1 Pt 2):285–289.
   PubMed Web of Science ®Google Scholar
• Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953–959.
   PubMed Web of Science ®Google Scholar
• Scrima L, Hartman PG, Johnson FH Jr, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990 Dec;13(6):479–490.
   PubMed Web of Science ®Google Scholar
• Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report, in narcolepsy. New York (NY): Spectrum; 1976. p. 59–67.
   Google Scholar
• Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979 Feb;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med. 1992 Apr;156(4):380–384.
   PubMedGoogle Scholar
• Scrima L, Hartman PG, Johnson FH Jr, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry. 1989 Aug;26(4):331–343.
   PubMed Web of Science ®Google Scholar
• Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002 Feb 1;25(1):42–49.
   PubMed Web of Science ®Google Scholar
• Group USXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003 Feb 1;26(1):31–35.
   PubMed Web of Science ®Google Scholar
• Group USXMS. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004 Mar;5(2):119–123.
   PubMed Web of Science ®Google Scholar
• Plazzi G, Pizza F, Vandi S, et al. Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy. Sleep Med. 2014;15(9):1046–1054.
   PubMed Web of Science ®Google Scholar
• Boscolo-Berto R, Viel G, Montagnese S, et al. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012 Oct;16(5):431–443.
   PubMed Web of Science ®Google Scholar
• Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8(4):451–458.
   PubMed Web of Science ®Google Scholar
• Mack RB. Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. N C Med J. 1993 May;54(5):232–233.
   PubMedGoogle Scholar
• Wong CG, Gibson KM, Snead OC 3rd. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci. 2004 Jan;25(1):29–34.
   PubMed Web of Science ®Google Scholar
• Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63(1):1–22.
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006 Jul;29(7):939–946.
   PubMed Web of Science ®Google Scholar
• Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs. 2007;21(4):337–354.
   PubMed Web of Science ®Google Scholar
• Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45(4):353–356.
   PubMed Web of Science ®Google Scholar
• Bhattacharya I, Boje KM. GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier. J Pharmacol Exp Ther. 2004 Oct;311(1):92–98.
   PubMed Web of Science ®Google Scholar
• Laborit H, Buchard F, Laborit G, et al. [Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation]. Agressologie. 1960 Nov;1:549–560.
   PubMedGoogle Scholar
• Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature. 1963;200:1207–1208.
   PubMed Web of Science ®Google Scholar
• Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol. 1997 Feb;51(3):337–361.
   PubMed Web of Science ®Google Scholar
• Castelli MP, Mocci I, Langlois X, et al. Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res Mol Brain Res. 2000 May 31;78(1–2):91–99.
   PubMedGoogle Scholar
• Snead OC 3rd. The ontogeny of [3H]gamma-hydroxybutyrate and [3H]GABAB binding sites: relation to the development of experimental absence seizures. Brain Res. 1994;659(1–2):147–156.
   PubMed Web of Science ®Google Scholar
• Crunelli V, Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci. 2002 May;3(5):371–382.
   PubMed Web of Science ®Google Scholar
• Poldrugo F, Addolorato G. The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol. 1999 Jan–Feb;34(1):15–24.
   PubMed Web of Science ®Google Scholar
• Castelli MP, Pibiri F, Carboni G, et al. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. CNS Drug Rev. 2004 Fall;10(3):243–260.
   PubMedGoogle Scholar
• Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). Faseb J. 2003;17(12):1691–1693.
   PubMed Web of Science ®Google Scholar
• Kemmel V, Taleb O, Andriamampandry C, et al. Gamma-hydroxybutyrate receptor function determined by stimulation of rubidium and calcium movements from NCB-20 neurons. Neuroscience. 2003;116(4):1021–1031.
   PubMed Web of Science ®Google Scholar
• Kemmel V, Taleb O, Perard A, et al. Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons. Neuroscience. 1998;86(3):989–1000.
   PubMed Web of Science ®Google Scholar
• Wu MF, Gulyani SA, Yau E, et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience. 1999;91(4):1389–1399.
   PubMed Web of Science ®Google Scholar
• Szabadi E. GHB for cataplexy: possible mode of action. J Psychopharmacol. 2015 Jun;29(6):744–749.
   PubMed Web of Science ®Google Scholar
• Wong CG, Chan KF, Gibson KM, et al. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev. 2004;23(1):3–20.
   PubMedGoogle Scholar
• Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4649–4654.
   PubMed Web of Science ®Google Scholar
• Schatzberg SJ, Cutter-Schatzberg K, Nydam D, et al. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med. 2004;18(4):586–588.
   PubMed Web of Science ®Google Scholar
• Kantor S, Mochizuki T, Janisiewicz AM, et al. Orexin neurons are necessary for the circadian control of REM sleep. Sleep. 2009 Sep;32(9):1127–1134.
   PubMed Web of Science ®Google Scholar
• Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239–14247.
   PubMed Web of Science ®Google Scholar
• Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941–946.
   PubMed Web of Science ®Google Scholar
• Mishima K, Fujiki N, Yoshida Y, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep. 2008;31(8):1119–1126.
   PubMed Web of Science ®Google Scholar
• Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9965–9970.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Lin L, Tanaka S, et al. Anti-tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33(7):869–874.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73(16):1333–1334.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004 Dec;56(6):905–908.
   PubMed Web of Science ®Google Scholar
• Bergstrom DL, Keller C. Narcolepsy: pathogenesis and nursing care. J Neurosci Nurs. 1992 Jun;24(3):153–157.
   PubMedGoogle Scholar
• Nishino S, Ripley B, Mignot E, et al. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002;110(1):1–7.
   PubMed Web of Science ®Google Scholar
• Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009;32(2):181–187.
   PubMed Web of Science ®Google Scholar
• Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res. 1990 Jul 23;523(2):325–330.
   PubMed Web of Science ®Google Scholar
• John J, Thannickal TC, McGregor R, et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol. 2013;74(6):786–793.
   PubMed Web of Science ®Google Scholar
• Valko PO, Gavrilov YV, Yamamoto M, et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol. 2013;74(6):794–804.
   PubMed Web of Science ®Google Scholar
• Bassetti CL, Baumann CR, Dauvilliers Y, et al. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res. 2010 Dec;19(4):620–623.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Delallee N, Jaussent I, et al. Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep. 2012;35(10):1359–1366.
   PubMed Web of Science ®Google Scholar
• Soya A, Song YH, Kodama T, et al. CSF histamine levels in rats reflect the central histamine neurotransmission. Neurosci Lett. 2008;430(3):224–229.
   PubMed Web of Science ®Google Scholar
• Shiba T. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep. 2004;27(suppl):A241–A242.
   Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30(1):74–83.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013 Nov;12(11):1068–1075.
   PubMed Web of Science ®Google Scholar
• Sharif NA, To ZP, Whiting RL. Analogs of thyrotropin-releasing hormone (TRH): receptor affinities in brains, spinal cords, and pituitaries of different species. Neurochem Res. 1991 Feb;16(2):95–103.
   PubMed Web of Science ®Google Scholar
• Riehl J, Honda K, Kwan M, et al. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology. 2000 Jul;23(1):34–45.
   PubMed Web of Science ®Google Scholar
• Nicoll RA. Excitatory action of TRH on spinal motoneurones. Nature. 1977;265(5591):242–243.
   PubMed Web of Science ®Google Scholar
• Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997 Aug 15;17(16):6401–6408.
   PubMed Web of Science ®Google Scholar
• Sharp T, Bennett GW, Marsden CA. Thyrotrophin-releasing hormone analogues increase dopamine release from slices of rat brain. J Neurochem. 1982 Dec;39(6):1763–1766.
   PubMed Web of Science ®Google Scholar
• Heuer H, Schafer MK, O’Donnell D, et al. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol. 2000;428(2):319–336.
   PubMed Web of Science ®Google Scholar
• Keller HH, Bartholini G, Pletscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature. 1974;248(448):528–529.
   PubMed Web of Science ®Google Scholar
• Broberger C. Neurotransmitters switching the thalamus between sleep and arousal: functional effects and cellular mechanism. New frontiers in neuroscience research; Showa University International Symposium for Life Science. 1st Annual Meeting; 2004 Aug 31; Tokyo. Showa University Kamijo Hall.
   Google Scholar
• Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep. 2005 Jun;28(6):754–763.
   PubMed Web of Science ®Google Scholar
• Okura M, Riehl J, Mignot E, et al. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology. 2000 Nov;23(5):528–538.
   PubMed Web of Science ®Google Scholar
• Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol. 2007 Feb;7(1):33–38.
   PubMed Web of Science ®Google Scholar
• Jordan W, Tumani H, Cohrs S, et al. Narcolepsy increased L-PGDS (beta-trace) levels correlate with excessive daytime sleepiness but not with cataplexy. J Neurol. 2005;252:1372–1378.
   PubMed Web of Science ®Google Scholar
• Sagawa Y, Sato M, Nishino S. Wake-promoting effects of ONO-4127, a prostaglandin DP1 receptor antagonist, in hypocretin deficient narcoleptic mice. J Sleep Sleep Disorders Res. 2013;36:Abstract Supplement.
   Google Scholar
• Leu-Semenescu S, Nittur N, Golmard JL, et al. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med. 2014 Jun;15(6):681–687.
   PubMed Web of Science ®Google Scholar
• Nishino S, Mignot E. Narcolepsy and cataplexy. Handb Clin Neurol. 2011;99:783–814.
   PubMedGoogle Scholar